Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have received a consensus rating of “Hold” from the eight ...

Cambridge: 2seventy bio, Inc. has announced a definitive merger agreement under which Bristol Myers Squibb will acquire all ...

Inc. has announced a definitive merger agreement under which BMS will acquire all of the outstanding shares of 2seventy bio.

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY agreed to acquire 2seventy bio, Inc TSVT. Meanwhile, other pipeline and ...

Multiple myeloma cell therapy Abecma is the lone remaining asset of 2seventy Bio, which spun out from Bluebird Bio ...

Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Leerink Partners reiterated their market perform rating on shares of 2seventy bio (NASDAQ:TSVT – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. The brokerage ...

Investorideas ( ), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for 2seventy bio ...

Shareholder Alert: The Ademi Firm investigates whether 2seventy bio, Inc. is obtaining a Fair Price for its Public Shareholders The Ademi Firm is investigating 2seventy bio (Nasdaq: TSVT) for possible ...

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

TSVT gained 5.26% after the company announced a definitive merger agreement with Bristol Myers Squibb BMY. Per the terms of ...